Atika Capital Management’s Heron Therapeutics HRTX Stock Holding History

Atika Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-90,000	Closed	-$1.63M	–	77
2017 Q4	$1.63M	Hold	90,000	–	–	0.63%	57
2017 Q3	$1.45M	Buy	90,000 +12,000	+15%	+$188K	0.42%	64
2017 Q2	$1.08M	Sell	78,000 -17,000	-18%	-$246K	0.38%	67
2017 Q1	$1.43M	Buy	+95,000	New	+$1.31M	0.7%	51

Other funds holding HRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Atika Capital Management's HRTX Position: Q1 2018 in Review

Atika Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2018, closing a stake of 90,000 shares — an estimated $1.63M sold.

Atika Capital Management first reported a position in HRTX in Q1 2017 and held it in 4 quarters. The position peaked at $1.63M in Q4 2017. 152 funds tracked by Wall St. Rank hold HRTX as of Q1 2018.

Atika Capital Management reported no remaining Heron Therapeutics position as of Q1 2018 after selling out during the quarter.
Atika Capital Management sold 90,000 Heron Therapeutics shares in Q1 2018, an estimated $1.63M.
Atika Capital Management first reported a position in Heron Therapeutics in Q1 2017 and held it in 4 quarters.
Atika Capital Management's Heron Therapeutics position peaked at $1.63M in Q4 2017.
152 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2018.

Based on Atika Capital Management's 13F filing for Q1 2018, filed 15 May 2018.